Current SARS-CoV-2 vaccines
| Vaccine | Nomenclature | Type/vector | Antigen | US approval | European approval |
|---|---|---|---|---|---|
| Moderna | mRNA-1273 | mRNA in lipid nanoparticles | Stabilized, prefusion spike protein | Emergency Use Authorization (EUA) | Conditional Marketing Authorisation (CMA) |
| Pfizer-BioNTech | BNT162b2 (EU-Cominarty) | mRNA in lipid nanoparticles | Stabilized, prefusion spike protein | EUA | CMA |
| Johnson & Johnson/Janssen | Ad26.COV2-S | Adenovirus 26 (species A) | Stabilized, prefusion spike protein | EUA | CMA |
| Astra-Zeneca | ChAdOx1 nCoV19 (AZD1222, Vaxzevria) | Chimpanzee adenovirus (species E) | Unmodified spike protein | – | CMA |